Maze Therapeutics (MAZE) Competitors $23.25 -0.05 (-0.21%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MAZE vs. KNSA, OGN, CPRX, TARS, ALVO, OCUL, CGON, IDYA, IBRX, and DNLIShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), Alvotech (ALVO), Ocular Therapeutix (OCUL), CG Oncology (CGON), IDEAYA Biosciences (IDYA), ImmunityBio (IBRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Kiniksa Pharmaceuticals International Organon & Co. Catalyst Pharmaceuticals Tarsus Pharmaceuticals Alvotech Ocular Therapeutix CG Oncology IDEAYA Biosciences ImmunityBio Denali Therapeutics Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Which has higher valuation and earnings, KNSA or MAZE? Maze Therapeutics has lower revenue, but higher earnings than Kiniksa Pharmaceuticals International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.40-$43.19M$0.04914.00Maze Therapeutics$167.50M6.09$52.23MN/AN/A Do insiders & institutionals hold more shares of KNSA or MAZE? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is KNSA or MAZE more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Maze Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Maze Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Maze Therapeutics N/A N/A N/A Do analysts prefer KNSA or MAZE? Kiniksa Pharmaceuticals International currently has a consensus target price of $41.17, suggesting a potential upside of 12.60%. Maze Therapeutics has a consensus target price of $32.67, suggesting a potential upside of 40.50%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to KNSA or MAZE? In the previous week, Maze Therapeutics had 20 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 31 mentions for Maze Therapeutics and 11 mentions for Kiniksa Pharmaceuticals International. Maze Therapeutics' average media sentiment score of 0.74 beat Kiniksa Pharmaceuticals International's score of 0.61 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 10 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKiniksa Pharmaceuticals International beats Maze Therapeutics on 7 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3874.9226.41Price / Sales6.09243.79457.0188.61Price / Cash152.1644.4425.8129.91Price / Book-3.279.6413.256.28Net Income$52.23M-$53.20M$3.29B$270.38M7 Day Performance55.31%0.44%0.47%2.70%1 Month Performance72.22%4.26%4.59%5.99%1 Year PerformanceN/A9.43%73.41%25.94% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$23.25-0.2%$32.67+40.5%N/A$1.02B$167.50M0.00121News CoverageAnalyst ForecastHigh Trading VolumeKNSAKiniksa Pharmaceuticals International2.2178 of 5 stars$35.71+0.6%$41.17+15.3%+46.9%$2.63B$423.24M892.97220Short Interest ↑OGNOrganon & Co.4.5137 of 5 stars$10.37+7.1%$17.33+67.2%-48.0%$2.52B$6.40B3.854,000Positive NewsCPRXCatalyst Pharmaceuticals4.9564 of 5 stars$20.29+2.5%$33.20+63.6%-1.2%$2.48B$558.50M12.3080Positive NewsAnalyst DowngradeTARSTarsus Pharmaceuticals2.5063 of 5 stars$57.63+0.3%$66.67+15.7%+48.4%$2.42B$182.95M-24.7350Positive NewsALVOAlvotech3.7634 of 5 stars$8.33+3.6%$14.00+68.1%-25.7%$2.42B$491.98M36.221,032Positive NewsShort Interest ↓OCULOcular Therapeutix4.0173 of 5 stars$13.60+7.1%$17.20+26.5%+42.3%$2.37B$56.66M-10.63230News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeCGONCG Oncology2.3989 of 5 stars$33.07+6.9%$54.30+64.2%-4.2%$2.36B$1.14M-18.6861Analyst ForecastInsider TradeGap UpHigh Trading VolumeIDYAIDEAYA Biosciences3.9704 of 5 stars$27.16+5.1%$45.77+68.5%-34.3%$2.26B$7M-7.1780Analyst ForecastIBRXImmunityBio2.5067 of 5 stars$2.40+0.4%$10.75+347.9%-27.4%$2.26B$14.74M-5.00590DNLIDenali Therapeutics4.3699 of 5 stars$15.43+4.3%$33.62+117.9%-53.9%$2.26BN/A-5.51430Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Kiniksa Pharmaceuticals International Competitors Organon & Co. Competitors Catalyst Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Alvotech Competitors Ocular Therapeutix Competitors CG Oncology Competitors IDEAYA Biosciences Competitors ImmunityBio Competitors Denali Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MAZE Stock Alerts